Related Experiment Video
Updated: Mar 20, 2026

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats
Published on: December 2, 2016
Rho Kinases and Cardiac Remodeling
1Section of Cardiology, Department of Medicine, University of Chicago.
Insights
Rho-associated coiled-coil containing kinases (ROCKs) contribute to cardiac fibrosis and hypertrophy. ROCK inhibition, using drugs like fasudil, shows therapeutic potential for treating hypertensive cardiac remodeling and heart failure.
Area of Science:
- Cardiovascular Biology
- Molecular Medicine
- Pharmacology
Background:
- Hypertensive cardiac remodeling involves left ventricular hypertrophy and fibrosis, potentially leading to heart failure.
- Rho-associated coiled-coil containing kinases (ROCKs), specifically ROCK1 and ROCK2, mediate RhoA signaling and are implicated in cardiovascular diseases.
Purpose of the Study:
- To review the role of ROCKs in cardiac fibrosis and hypertrophy.
- To discuss the therapeutic potential of ROCK inhibition for cardiac remodeling.
Main Methods:
- Review of experimental studies on ROCKs in cardiac remodeling.
- Analysis of data from ROCK inhibitor (e.g., fasudil) studies.
- Examination of findings from genetically modified mouse models lacking ROCK isoforms.
Main Results:
- ROCKs contribute to cardiac fibrosis and hypertrophy in pathological conditions.
- ROCK inhibition demonstrates beneficial effects in experimental models of cardiac remodeling.
- Genetic deletion of ROCK isoforms reduces myocardial fibrosis.
Conclusions:
- ROCKs are key contributors to deleterious cardiac remodeling.
- ROCKs represent promising therapeutic targets for cardiovascular diseases.
- ROCK inhibition warrants further investigation for treating heart failure with preserved ejection fraction.
Abstract:
Hypertensive cardiac remodeling is characterized by left ventricular hypertrophy and interstitial fibrosis, which can lead to heart failure with preserved ejection fraction. The Rho-associated coiled-coil containing kinases (ROCKs) are members of the serine/threonine protein kinase family, which mediates the downstream effects of the small GTP-binding protein RhoA. There are 2 isoforms: ROCK1 and ROCK2. They have different functions in different types of cells and tissues. There is growing evidence that ROCKs contribute to the development of cardiovascular diseases, including cardiac fibrosis, hypertrophy, and subsequent heart failure. Recent experimental studies using ROCK inhibitors, such as fasudil, have shown the benefits of ROCK inhibition in cardiac remodeling. Mice lacking each ROCK isoform also exhibit reduced myocardial fibrosis in a variety of pathological models of cardiac remodeling. Indeed, clinical studies with fasudil have suggested that ROCKs could be potential novel therapeutic targets for cardiovascular diseases. In this review, we summarize the current understanding of the roles of ROCKs in the development of cardiac fibrosis and hypertrophy and discuss their therapeutic potential for deleterious cardiac remodeling. (Circ J 2016; 80: 1491-1498).
More Related Videos
Related Concept Videos
Receptor Tyrosine Kinases
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
MAPK Signaling Cascades
Pathophysiology of Heart Failure
Cardiomyopathy IV: Restrictive Cardiomyopathy

